PathoGenesis
Executive Summary
Off-label promotion of Tobi aerosol administration for the treatment of bronchiectasis could begin following publication of Phase II trial data in 1999, PathoGenesis Chief Financial Officer Alan Meyer declared Oct. 6 at the Warburg Dillon Read conference in New York. "With FDA regulations for modernization...I think we have a good shot that once we have that Phase II data published, we're going to be able to promote that" indication. PathoGenesis has completed enrollment of the Phase II bronchiectasis trial as well as an early in-patient portion of the trial, Meyer noted. The drug, marketed in the U.S. for the management of Pseudomonas aeruginosa infections in cystic fibrosis patients, is also being studied as a potential lung sterilizer to prevent the spread of tuberculosis
You may also be interested in...
PathoGenesis Tobi Use Per Patient Can Be Raised About 50%, CEO Says
PathoGenesis believes that per patient use of Tobi inhaled tobramycin can be increased by about 50%.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011